Anti-Snake Venom Neutralizing Antibody (LNX-D09) from ProteoGenix; catalogue ARO-A22657; research use only.
Know who made it. See the evidence. Buy through one marketplace.
The ultimate solution for snakebite treatment.
As its name suggests, LNX-D09 is a potent antibody designed specifically to neutralize the effects of snake venom. This innovative biotech product is the result of years of research and development, and has been proven to effectively counteract the harmful toxins found in various snake species.
LNX-D09 works by binding to the venom molecules and preventing them from attacking the body’s cells and tissues. This unique mechanism of action not only stops the venom from spreading, but also helps to reduce the severity of symptoms such as swelling, pain, and tissue damage.
LNX-D09 is primarily used as a treatment for snakebites, providing fast and effective relief for victims of venomous snake attacks. It can also be used as a preventive measure for individuals who are at high risk of encountering snakes, such as hikers, farmers, and field workers.
In addition to its use in snakebite treatment, LNX-D09 has shown promising results in experimental use cases. Researchers have found that it can also be effective in treating other conditions caused by venom, such as spider bites and scorpion stings. Furthermore, studies have shown that LNX-D09 may have potential applications in the development of anti-venom vaccines.
With its versatile applications and proven efficacy, LNX-D09 is a must-have in any first aid kit or medical facility. Its compact size and easy administration make it a convenient and reliable solution for snakebite emergencies.
When it comes to snakebite treatment, every second counts. That’s why LNX-D09 is a game-changer – providing a rapid and effective response to venomous bites. Don’t let snake venom take a toll on your health – arm yourself with LNX-D09 and be prepared for any encounter with these dangerous reptiles.
Keywords: snakebite treatment, anti-venom, venom neutralization, toxin binding, rapid relief, preventive measure, anti-venom vaccine, first aid kit, medical facility.
ProteoGenix catalogue number ARO-A22657. For research use only.
Target: long-chain neurotoxin; Clonality: Monoclonal Antibody; Applications: IP, Neutralization, SPR.
Available configurations: 50ug, 100ug, 1mg.
Fully tested in-house by ABMIUM, or supported by an advanced validation report from a partner reviewed by ABMIUM. Highest confidence. Non-conformities fully supported under the ABMIUM Product Promise.
Quality verified. Independent collaborator or expected-performance data available. Product meets ABMIUM quality standards.
Expected to work based on structural and biochemical data. Not yet directly tested by ABMIUM or a collaborator. No non-conformity support for this combination.
Not recommended for this application or species/sample combination. This may indicate either evidence of unsuitability or that the combination has not been tested and therefore cannot currently be recommended.
Evidence status by application and model.
| Target | WB | IHC-P | IHC-Fr | IF/ICC | Flow Cyt | IP | ChIP | ELISA | Neutralization | SPR |
|---|---|---|---|---|---|---|---|---|---|---|
| long-chain neurotoxin |
This product is manufactured by ProteoGenix and sold through ABMIUM without relabelling.
ABMIUM supports global orders. Availability, shipping requirements and applicable import arrangements are confirmed before fulfilment where required.
Yes. Send your target, sample, application and experimental conditions through ABMIUM MATCH or technical support.
Unless the listing expressly states otherwise, ABMIUM products are supplied for research use only and are not for diagnostic or therapeutic use.
